Duopharma Biotech Berhad (KLSE:DPHARMA)

Market Cap	1.16B -4.0%
Revenue (ttm)	916.83M +3.8%
Net Income	92.54M +26.7%
EPS	0.10 +26.6%
Shares Out	961.94M
PE Ratio	12.59
Forward PE	11.35
Dividend	0.05 (3.76%)
Ex-Dividend Date	Mar 12, 2026

Volume	380,600
Open	1.240
Previous Close	1.210
Day's Range	1.230 - 1.250
52-Week Range	1.200 - 1.570
Beta	0.36
Analysts	Strong Buy
Price Target	1.69 (+37.4%)
Earnings Date	Aug 14, 2026

About Duopharma Biotech Berhad

Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives under the Uphamol, Uphacol, and Uphaplast brand names; eyecare products under the Eye Glo brand name; antacids under the Alucid brand name; joint pain...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 1,957
• Stock Exchange: Bursa Malaysia
• Ticker Symbol: DPHARMA

Financial Performance

In 2025, Duopharma Biotech Berhad's revenue was 931.69 million, an increase of 14.50% compared to the previous year's 813.70 million. Earnings were 87.46 million, an increase of 39.62%.

Analyst Summary

According to 5 analysts, the average rating for DPHARMA stock is "Strong Buy." The 12-month stock price target is RM 1.69, which is an increase of 37.40% from the latest price.

Price Target

RM 1.69

(37.40% upside)

Analyst Consensus: Strong Buy